Alginates: From the ocean to gastroesophageal reflux disease treatment

1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20; quiz 1943. [CrossRef]
2. Spechler SJ, Jain SK, Tendler DA, Parker RA. Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002; 16: 1795-800. [CrossRef]
3. Roman S, Gyawali CP, Savarino E, et al. Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group. Neurogastroenterol Motil 2017; 29: 1-15. [CrossRef]
4. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2014; 63: 871-80. [CrossRef]
5. Richter JE, Rubenstein JH. Presentation and Epidemiology of Gastroesophageal Reflux Disease. Gastroenterology 2018; 154: 267-76. [CrossRef]
6. Bor S, Mandiracioglu A, Kitapcioglu G, Caymaz-Bor C, Gilbert RJ. Gastroesophageal reflux disease in a low-income region in Turkey. Am J Gastroenterol 2005; 100: 759-65. [CrossRef]
7. Yonem O, Sivri B, Ozdemir L, Nadir I, Yuksel S, Uygun Y. Gastroesophageal reflux disease prevalence in the city of Sivas. Turk J Gastroenterol 2013; 24: 303-10. [CrossRef]
8. Ülkü D. Bolu ili merkezinde GÖRH prevalansı. UGH, Antalya. 2012.
9. Bor S, Vardar R, Vardar E, Takmaz S, Mungan ZA. Endoscopic findings of gastroesophageal reflux disease in Turkey: Multicenter prospective study (Gorhen). Gastroenterology 2008; 134: 4(Suppl 1); A-600. [CrossRef]
10. Bor S, Kitapcioglu G, Kasap E. Prevalence of gastroesophageal reflux disease in a country with a high occurrence of Helicobacter pylori. World J Gastroenterol 2017; 23: 525-32. [CrossRef]
11. Mungan Z. Prevalence and demographic determinants of gastroesophageal reflux disease (GERD) in the Turkish general population: a population-based cross-sectional study. Turk J Gastroenterol 2012; 23: 323-32. [CrossRef]
12. Bor S, Sarıtaş Yüksel E. How is the gastroesophageal reflux disease prevalence, incidence, and frequency of complications (stricture/esophagitis/Barrett’s esophagus/carcinoma) in Turkey compared to other geographical regions globally? Turk J Gastroenterol 2017; 28(Suppl 1): S4-S9. [CrossRef]
13. Dent J, Becher A, Sung J, et al. Systematic Review: Patterns of Reflux-Induced Symptoms and Esophageal Endoscopic Findings in Large-Scale Surveys. Clin Gastroenterol Hepatol 2012; 10: 863-73.e3. [CrossRef]
14. Ronkainen J, Aro P, Storskrubb T, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol 2005; 40: 275-85. [CrossRef]
15. Zou D, He J, Ma X, et al. Epidemiology of symptom-defined gastroesophageal reflux disease and reflux esophagitis: The systematic investigation of gastrointestinal diseases in China (SILC). Scand J Gastroenterol 2011; 46: 133-41. [CrossRef]
16. Ou JL, Tu CC, Hsu PI, et al Prevalence and risk factors of erosive esophagitis in Taiwan. J Chin Med Assoc 2012; 75: 60-4. [CrossRef]
17. Yılmaz N, Tuncer K, Tunçyürek M, Özütemiz O, Bor S. The prevalence of Barrett’s esophagus, erosive esophagitis in a tertiary referral center in Turkey. Turk J Gastroenterol 2006; 17: 79-83.
18. Kang JY. Systematic review: geographical and ethnic differences in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004; 20: 705-17. [CrossRef]
19. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett’s esophagus in asymptomatic individuals. Gastroenterology 2002; 123: 461-7. [CrossRef]
20. Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003; 125: 1670-7. [CrossRef]
21. Shiota S, Singh S, Anshasi A, El-Serag HB. Prevalence of Barrett’s Esophagus in Asian Countries: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2015; 13: 1907-18. [CrossRef]
22. Toruner M, Soykan I, Ensari A, Kuzu I, Yurdaydin C, Ozden A. Barrett’s esophagus: prevalence and its relationship with dyspeptic symptoms. J Gastroenterol Hepatol 2004; 19: 535-40. [CrossRef]
23. Odemis B, Cicek B, Zengin NI, et al. Barrett’s esophagus and endoscopically assessed esophagogastric junction integrity in 1000 consecutive Turkish patients undergoing endoscopy: a prospective study. Dis Esophagus 2009; 22: 649-55. [CrossRef]
24. Loffeld RJ, van der Putten AB. Prevalence of gastroesophageal reflux disease in immigrants living in the Zaanstreek region in the Netherlands. Dis Esophagus 2004; 17: 87-90. [CrossRef]
25. Coleman HG, Xie SH, Lagergren J. The Epidemiology of Esophageal Adenocarcinoma. Gastroenterology 2018; 154: 390-405. [CrossRef]
26. Dettmar PW, Gil-Gonzalez D, Fisher J, et al. A comparative study on the raft chemical properties of various alginate antacid raft-forming products. Drug Dev Ind Pharm 2018; 44: 30-9. [CrossRef]
27. Hampson FC, Farndale A, Strugala V, Sykes J, Jolliffe IG, Dettmar PW. Alginate rafts and their characterisation. Int J Pharm 2005; 27; 294: 137-47. [CrossRef]
28. Kwiatek MA, Roman S, Fareeduddin A, Pandolfino JE, Kahrilas PJ. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial ‘acid pocket’ in symptomatic GERD patients. Aliment Pharmacol Ther 2011; 34: 59-66. [CrossRef]
29. Kahrilas PJ, McColl K, Fox M, et al. The acid pocket: a target for treatment in reflux disease? Am J Gastroenterol 2013; 108: 1058-64. [CrossRef]
30. Strugala V, Avis J, Jolliffe IG, Johnstone LM, Dettmar PW. The role of an alginate suspension on pepsin and bile acids - key aggressors in the gastric refluxate. Does this have implications for the treatment of gastro-oesophageal reflux disease? J Pharm Pharmacol 2009; 61: 1021-8. [CrossRef]
31. Woodland P, Batista-Lima F, Lee C, Preston SL, Dettmar P, Sifrim D. Topical protection of human esophageal mucosal integrity. Am J Physiol Gastrointest Liver Physiol 2015; 308: G975-80. [CrossRef]
32. Woodland P, Lee C, Duraisamy Y, Farré R, Dettmar P, Sifrim D. Assessment and protection of esophageal mucosal integrity in patients with heartburn without esophagitis. Am J Gastroenterol 2013; 108: 535-43. [CrossRef]
33. Leiman DA, Riff BP, Morgan S, et al. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Dis Esophagus 2017; 30: 1-9. [CrossRef]
34. Mitchell DR, Derakhshan MH, Robertson EV, McColl KE. The role of the acid pocket in gastroesophageal reflux disease. J Clin Gastroenterol 2016; 50: 111-9. [CrossRef]
35. Dettmar PW, Sykes J, Little SL, Bryan J. Rapid onset of effect of sodium alginate on gastro-oesophageal reflux compared with ranitidine and omeprazole, and relationship between symptoms and reflux episodes. Int J Clin Pract 2006; 60: 275-83. [CrossRef]
36. De Ruigh A, Roman S, Chen J, Pandolfino JE, Kahrilas PJ. Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study. Aliment Pharmacol Ther 2014; 40: 531-7. [CrossRef]
37. Mandel KG, Daggy BP, Brodie DA, Jacoby HI. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther 2000; 14: 669-90. [CrossRef]
38. Lai IR, Wu MS, Lin JT. Prospective, randomized, and active controlled study of the efficacy of alginic acid and antacid in the treatment of patients with endoscopy-negative reflux disease. World J Gastroenterol 2006; 12: 747-54. [CrossRef]
39. Pouchain D, Bigard MA, Liard F, et al. Gaviscon(R) vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. A direct comparative randomised trial. BMC Gastroenterol 2012; 12: 18. [CrossRef]
40. Çelebi A, Yılmaz H. What is proton pump inhibitors unresponsiveness in gastroesophageal reflux disease? How should these cases be managed? Turk J Gastroenterol 2017; 28(Suppl 1): S71-S2. [CrossRef]
41. Beeley M, Warner JO. Medical treatment of symptomatic hiatus hernia with low-density compounds. Curr Med Res Opin 1972; 1: 63- 9. [CrossRef]
42. Chevrel B. A comparative crossover study on the treatment of heartburn and epigastric pain: liquid Gaviscon and a magnesium-aluminium antacid gel. J Int Med Res 1980; 8: 300-2. [CrossRef]
43. Goves J, Oldring J K, Kerr D, et al. First line treatment with omeprazole provides an effective and superior alternative strategy in the management of dyspepsia compared to antacid/alginate liquid: a multicentre study in general practice. Aliment Pharmacol Ther 1998; 12: 147-57. [CrossRef]
44. Chiu CT, Hsu CM, Wang CC, et al. Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease. Aliment Pharmacol Ther 2013; 38: 1054-64. [CrossRef]
45. Giannini EG, Zentilin P, Dulbecco P, et al. A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms. Dig Dis Sci 2006; 51: 1904-9. [CrossRef]
46. Chatfield S. A comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastro-oesophageal reflux disease. Curr Med Res Opin 1999; 15: 152-9. [CrossRef]
47. Sun J, Yang C, Zhao H, et al. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China. Aliment Pharmacol Ther 2015; 42: 845-54. [CrossRef]
48. Manabe N, Yoshihara M, Sasaki A, Tanaka S, Haruma K, Chayama K. Clinical characteristics and natural history of patients with low-grade reflux esophagitis. J Gastroenterol Hepatol 2002; 17: 949-54. [CrossRef]
49. Manabe N, Haruma K, Ito M, et al. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial. Dis Esophagus 2012; 25: 373-80. [CrossRef]
50. Reimer C, Ng B, Smith G, Wilkinson J, Reader S, Bytzer P. Concentrated Alginate As Add-On Therapy in Gastro-Esophageal Reflux Disease (GERD) Patients With Inadequate Response to Once Daily Proton Pump Inhibitor (PPI): A Multicentre, Randomized, Double-Blind, Placebo-Controlled Pilot Study. Gastroenterology 2015; 148: S135-6. [CrossRef]
51. Coyle C, Crawford G, Wilkinson J, Thomas SJ, Bytzer P. Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms. Aliment Pharmacol Ther 2017; 45: 1524-33. [CrossRef]
52. Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2 receptor antagonists and prokinetics for gastro-oesophageal reflux disease like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2013; 5: CD002095.
53. Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut 2012; 61: 1340-54. [CrossRef]
54. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010; 32: 720-37. [CrossRef]
55. Ranaldo N, Losurdo G, Iannone A, et al. Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease. Cell Death Dis 2017; 8: e3040. [CrossRef]
56. Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol 2011; 106: 1419-25. [CrossRef]
57. Boeckxstaens G, El-Serag HB, Smout AJ, Kahrilas PJ. Symptomatic reflux disease: the present, the past and the future. Gut 2014; 63: 1185-93. [CrossRef]
58. Zerbib F, Duriez A, Roman S, Capdepont M, Mion F. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut 2008; 57: 156-60. [CrossRef]
59. Thomas E, Wade A, Crawford G, Jenner B, Levinson N, Wilkinson J. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2014; 39: 595- 602. [CrossRef]
60. Wilkinson J, Wade A, Thomas SJ, Jenner B, Hodgkinson V, Coyle C. Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2019; 31: 86-93. [CrossRef]
61. Akyüz F, Mutluay Soyer Ö. How is gastroesophageal reflux disease classified? Turk J Gastroenterol 2017; 28(Suppl 1): S10-S11. [CrossRef]
62. Cappell MS. Clinical presentation, diagnosis, and management of gastroesophageal reflux disease. Med Clin North Am 2005; 89: 243-91. [CrossRef]
63. Fraser-Kirk K. Laryngopharyngeal reflux: A confounding cause of aerodigestive dysfunction. Aust Fam Physician 2017; 46: 34-9.
64. Jaspersen D, Kulig M, Labenz J, et al. Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study. Aliment Pharmacol Ther 2003; 17: 1515-20. Erratum in: Aliment Pharmacol Ther 2003; 18: 355. [CrossRef]
65. Gyawali CP, Fass R. Management of Gastroesophageal Reflux Disease. Gastroenterology, 2018; 154: 302-18. [CrossRef]
66. Achem SR, Kolts BE, MacMath T, et al. Effects of omeprazoleversus placebo in treatment of noncardiac chestpain and gastroesophageal reflux. Dig Dis Sci 1997; 42: 2138-45. [CrossRef]
67. Ours TM, Kavuru MS, Schilz RJ, Richter JE. A prospective evaluation of esophageal testing and a double-blind, randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough. Am J Gastroenterol 1999; 94: 3131-8. [CrossRef]
68. Chang AB, Lasserson TJ, Gaffney J, et al. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev 2005; 4: CD004823. [CrossRef]
69. Lieder A, Issing W. Treatment for resilient cough owing to laryngopharyngeal reflux with a combination of proton pump inhibitor and Gaviscon Advance: how we do it. Clin Otolaryngol 2011; 36: 583-7. [CrossRef]
70. Tack J. Review article: the role of bile and pepsin in the pathophysiology and treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006; 24(Suppl 2): 10-6. [CrossRef]
71. Park W, Hicks DM, Khandwala F, et al. Laryngopharyngealreflux: prospective cohort study evaluating optimal dose ofproton-pump inhibitor therapy and pretherapy predictors ofresponse. Laryngoscope 2005; 115: 1230-8. [CrossRef]
72. Williams RB, Szczesniak MM, Maclean JC, et al. Predictors ofoutcome in an open label, therapeutic trial of high-dose omeprazolein laryngitis. Am J Gastroenterol 2004; 99: 777-85. [CrossRef]
73. Vaezi MF, Richter JE, Stasney CR, et al. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope 2006; 116: 254-60. [CrossRef]
74. Hom C, Vaezi MF. Extra-esophageal manifestations of gastroesophageal reflux disease: diagnosis and treatment. Drugs 2013; 73: 1281-95. [CrossRef]
75. Washington N. Investigation into the barrier action of an alginate gastric reflux suppressant, Liquid Gaviscon. Drug Invest 1990; 2: 23-3. [CrossRef]
76. McGlashan JA, Johnstone LM, Sykes J, Strugala V, Dettmar PW. The value of a liquid alginate suspension (Gaviscon Advance) in the management of laryngopharyngeal reflux. Eur Arch Otorhinolaryngol 2009; 266: 243-51. [CrossRef]
77. Tseng WH, Tseng PH, Wu JF, et al. Double-blind, placebo-controlled study with alginate suspension for laryngopharyngeal reflux disease. Laryngoscope 2018; 128: 2252-60. [CrossRef]
78. Wilkie MD, Fraser HM, Raja H. Gaviscon Advance alone versus co-prescription of Gaviscon Advance and proton pump inhibitors in the treatment of laryngopharyngeal reflux. Eur Arch Otorhinolaryngol 2018; 275: 2515-21. [CrossRef]
79. Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656-64. [CrossRef]
80. Bor S, Kalkan İH. Medical treatment of gastroesophageal reflux disease. Turk J Gastroenterol 2017; 28(Suppl 1): S48-S52. [CrossRef]
81. Gyawali CP. Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe. Curr Gastroenterol Rep 2017; 19(9): 46. [CrossRef]
82. Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Longterm Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology 2017; 152: 706-15. [CrossRef]
83. Metz DC, Inadomi JM, Howden CW, van Zanten SJ, Bytzer P. On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol 2007; 102: 642-53. [CrossRef]
84. Domingues G, Moraes-Filho JP. Noncompliance is an impact factor in the treatment of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol 2014; 8: 761-5. [CrossRef]
85. Çelebi A, Aydin D, Kocaman O, Konduk B, Senturk O, Hulagu S. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. Turk J Gastroenterol 2016; 27: 408-14. [CrossRef]
86. Washington N. Antacids and Anti-Reflux Agents. BocaRaton, FL, USA: CRC Press Inc., 1991: 215.
87. Katsanos KH, Tasolambrou C, Christodoulopoulou A, et al. Comparison of the step down disease (GERD): Results of a randomized open-label pilot study with omeprazole in Northwest Greece. Ann Gastroenterol 2003; 16: 138-50.
88. Eggleston A, Wigerinck A, Huijghebaert S, Dubois D, Haycox A. Cost-effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis. Gut 1998; 42: 13-6. [CrossRef]
89. Hixson L J, Kelley CL, Jones WN, Tuohy CD. Current trends in the pharmacotherapy for gastroesophageal reflux disease. Arch Intern Med 1992; 152: 717-23. [CrossRef]
90. Habu Y, Maeda K, Kusuda T, et al. “Proton-pump inhibitor-first” strategy versus “step-up” strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan. J Gastroenterol 2005; 40(11): 1029-35. [CrossRef]
91. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106 -10. [CrossRef]
92. Gough AL, Long RG, Cooper BT, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagits. Aliment Pharmacol Ther 1996; 10: 529-39. [CrossRef]
93. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol 2009; 104(Suppl 2): S27-S32. [CrossRef]
94. Kim J, Blackett JW, Jodorkovsky D. Strategies for Effective Discontinuation of Proton Pump Inhibitors. Curr Gastroenterol Rep. 2018;20(6):27. [CrossRef]
95. Surdea-Blaga T, Băncilă I, Dobru D, et al. Mucosal Protective Compounds in the Treatment of Gastroesophageal Reflux Disease. A Position Paper Based on Evidence of the Romanian Society of Neurogastroenterology. J Gastrointestin Liver Dis. 2016; 25:537- 546. [CrossRef]
96. Murie J, Allen J, Simmonds R, de Wet C. Glad you brought it up: a patient-centred programme to reduce proton-pump inhibitor prescribing in general medical practice. Qual Prim Care 2012; 20: 141-8.
97. Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2018; 66: 516-54. [CrossRef]
98. Nelson SP, Chen EH., Syniar GM, et al. Prevalence of symptoms of gastroesophageal reflux during infancy. A pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 1997; 151: 569-72. [CrossRef]
99. Singendonk MMJ, Rexwinkel R, Steutel NF, et al. Development of a Core Outcome Set for Infant Gastroesophageal Reflux Disease. J Pediatr Gastroenterol Nutr 2019; 68: 655-61. [CrossRef]
100. Tighe M, Afzal NA, Bevan A, et al. Pharmacological treatment of children with gastro-oesophageal reflux. Cochrane Database Syst Rev 2014; 11: CD008550. [CrossRef]
101. Davies I, Burman-Roy S, Murphy MS; Guideline Development Group. Gastro-oesophageal refluxdisease in children: NICE guidance. BMJ 2015; 350: g7703. [CrossRef]
102. Weldon AP, Robinson MJ. Trial of Gaviscon in the treatment of gastro-oesophageal refux in infancy. Aust Paediatr J 1972; 8: 279- 81. [CrossRef]
103. Vandenplas Y, Sacre-Smits L. Gastro-oesophageal reflux in infants: Evaluation of treatment by pH monitoring. Eur J Pediatr 1987; 146: 504-7. [CrossRef]
104. Le Luyer B, Mougenot JF, Mashako L, et al. Multicenter study of sodium alginate in the treatment of regurgitation in infants. Ann Pediatr 1992; 39: 635-40.
105. Le Luyer B, Mougenot JF, Mashako L, et al. Pharmacologic efficacy of sodium alginate suspension on gastro-esophageal reflux in infants and children. Arch Fr Pediatr 1990; 47: 65-8.
106. Maestri L. Treatment with sodium alginate of gastroesophageal reflux disease in childhood: efficacy and tolerance assessment. Pediatr Med Chir 2001; 23: 187-9.
107. Salvatore S, Ripepi A, Huysentruyt K, et al. The Effect of Alginate in Gastroesophageal Reflux in Infants. Paediatr Drugs 2018; 20: 575- 83. [CrossRef]
108. Forbes D, Hodgson M, Hill R. The effects of Gaviscon and metoclopramide in gastroesophageal reflux in children. J Pediatr Gastroenterol Nutr 1986; 5: 556-9. [CrossRef]
109. Buts JP, Barudi C, Otte JB. Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. Eur J Pediatr 1987; 146: 156-8. [CrossRef]
110. Oderda G, Dell’Olio D, Forni M, et al. Treatment of childhood peptic oesophagitis with famotidine or alginate-antacid. Ital J Gastroenterol 1990; 22: 346-9.
111. Greally P, Hampton FJ, MacFadyen UM, et al. Gaviscon and carobel compared with cisapride in gastro-oesophageal reflux. Arch Dis Child 1992; 67: 618-21 [CrossRef]
112. Carroccio A, Iacono G, Montalto G, et al. Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scand J Gastroenterol 1994; 29: 300-4. [CrossRef]
113. Borrelli O, Rea P, De Mesquita B, et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and lansoprazole for children with gastroesophageal reflux. Ital J Pediatr 2002; 28: 304-9.
114. Del Buono R, Wenzl TG, Ball G, et al. Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Arch Dis Child 2005; 90: 460-3. [CrossRef]
115. Cresi F, Savino F, Marinaccio C, et al. Gaviscon for gastro-oesophageal reflux in infants: a poorly effective treatment? Arch Dis Child 2006; 91: 93. [CrossRef]
116. Miller S. Comparison of the efficacy and safety of a new aluminum-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux. Curr Med Res Opin 1999; 15: 160-8. [CrossRef]
117. Ummarino D, Miele E, Martinelli M, et al. Effect of magnesium alginate plus simethicone on gastroesophageal reflux in infants. J Pediatr Gastroenterol Nutr 2015; 60: 230-5. [CrossRef]
118. Rossor T, Andradi G, Bhat R, et al. Investigation and management of gastro-oesophageal reflux in United Kingdom neonatal intensive care units. Acta Paediatr 2018; 107: 48-51. [CrossRef]
119. Atasay B, Erdeve O, Arsan S, et al. Effect of sodium alginate on acid gastroesophageal reflux disease in preterm infants: a pilot study. J Clin Pharmacol 2010; 50: 1267-72. [CrossRef]
120. Corvaglia L, Aceti A, Mariani E, et al. The efficacy of sodium alginate (Gaviscon) for the treatment of gastro-oesophageal reflux in preterm infants. Aliment Pharmacol Ther 2011; 33: 466-70. [CrossRef]
121. Corvaglia L, Spizzichino M, Zama D, et al. Sodium Alginate (Gaviscon) does not reduce apnoeas related to gastro-oesophageal reflux in preterm infants. Early Hum Dev 2011; 87: 775-8. [CrossRef]
122. Bilgin H, Eren A, Kara S. Gaviscon and domperidon responsive apnea episodes associated with gastro-esophageal reflux disase in twins. Asia Pac J Clin Nutr 2015; 24: 753-5.
123. Keady S. Update on drugsforgastro-oesophagealrefluxdisease. Arch Dis Child Educ Pract Ed. 2007; 92: ep114-8. [CrossRef]
124. Woodard-Knight L, Fudge A, Teubner J, et al. Aluminiumbsorptionandantacidtherapy in infancy. J Paediatr Child Health 1992; 28: 257-9. [CrossRef]
125. Tsou VM, Young RM, Hart MH, et al. Elevated plasmaa luminum levels in normal infants receiving antacids containing aluminum. Pediatrics 1991; 87: 148-51.
126. Hewitt GJ, Benham ES. A complication of Gaviscon in a neonate -’the Gavisconoma’. Aust Paediatr J 1976; 12: 47-8. [CrossRef]
127. Gawarammana IB, Coburn J, Greene S, et al. Severe hypokalaemic metabolic alkalosis following ingestion of gaviscon. Clin Toxicol 2007; 45: 176-8. [CrossRef]
128. Bosscher D, Van Caillie-Bertrand M, Deelstra H. Effect of thickening agents, based on soluble dietary fiber, on the availability of calcium, iron, and zinc from infant formulas. Nutrition 2001; 17: 614- 8. [CrossRef]
129. Dağlı Ü, Kalkan İH. Treatment of reflux disease during pregnancy and lactation. Turk J Gastroenterol 2017; 28(Suppl 1): S53-S56. [CrossRef]
130. Briggs GG, Freeman RY, Yaffe SJ. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Baltimore, USA: William and Wilkins, 2002.
131. Strugala V, Bassin J, Swales VS, Lindow SW, Dettmar PW, Thomas EC. Assessment of the Safety and Efficacy of a Raft-Forming Alginate Reflux Suppressant (Liquid Gaviscon) for the Treatment of Heartburn during Pregnancy. ISRN Obstet Gynecol 2012; 2012: 481870. [CrossRef]
132. Meteerattanapipat P, Phupong V. Efficacy of alginate-based reflux suppressant and magnesium-aluminium antacid gel for treatment of heartburn in pregnancy: a randomized double-blind controlled trial. Sci Rep 2017; 7: 44830. [CrossRef]

APA	Bor S, KALKAN İ, ÇELEBİ A, Dincer D, Akyuz F, dettmar p, ÖZEN H (2019). Alginates: From the ocean to gastroesophageal reflux disease treatment. , 109 - 136. 10.5152/tjg.2019.19677
Chicago	Bor Serhat,KALKAN İsmail Hakkı,ÇELEBİ Altay,Dincer Dinc,Akyuz Filiz,dettmar peter,ÖZEN Hasan Alginates: From the ocean to gastroesophageal reflux disease treatment. (2019): 109 - 136. 10.5152/tjg.2019.19677
MLA	Bor Serhat,KALKAN İsmail Hakkı,ÇELEBİ Altay,Dincer Dinc,Akyuz Filiz,dettmar peter,ÖZEN Hasan Alginates: From the ocean to gastroesophageal reflux disease treatment. , 2019, ss.109 - 136. 10.5152/tjg.2019.19677
AMA	Bor S,KALKAN İ,ÇELEBİ A,Dincer D,Akyuz F,dettmar p,ÖZEN H Alginates: From the ocean to gastroesophageal reflux disease treatment. . 2019; 109 - 136. 10.5152/tjg.2019.19677
Vancouver	Bor S,KALKAN İ,ÇELEBİ A,Dincer D,Akyuz F,dettmar p,ÖZEN H Alginates: From the ocean to gastroesophageal reflux disease treatment. . 2019; 109 - 136. 10.5152/tjg.2019.19677
IEEE	Bor S,KALKAN İ,ÇELEBİ A,Dincer D,Akyuz F,dettmar p,ÖZEN H "Alginates: From the ocean to gastroesophageal reflux disease treatment." , ss.109 - 136, 2019. 10.5152/tjg.2019.19677
ISNAD	Bor, Serhat vd. "Alginates: From the ocean to gastroesophageal reflux disease treatment". (2019), 109-136. https://doi.org/10.5152/tjg.2019.19677

APA	Bor S, KALKAN İ, ÇELEBİ A, Dincer D, Akyuz F, dettmar p, ÖZEN H (2019). Alginates: From the ocean to gastroesophageal reflux disease treatment. Turkish Journal of Gastroenterology, 30(2), 109 - 136. 10.5152/tjg.2019.19677
Chicago	Bor Serhat,KALKAN İsmail Hakkı,ÇELEBİ Altay,Dincer Dinc,Akyuz Filiz,dettmar peter,ÖZEN Hasan Alginates: From the ocean to gastroesophageal reflux disease treatment. Turkish Journal of Gastroenterology 30, no.2 (2019): 109 - 136. 10.5152/tjg.2019.19677
MLA	Bor Serhat,KALKAN İsmail Hakkı,ÇELEBİ Altay,Dincer Dinc,Akyuz Filiz,dettmar peter,ÖZEN Hasan Alginates: From the ocean to gastroesophageal reflux disease treatment. Turkish Journal of Gastroenterology, vol.30, no.2, 2019, ss.109 - 136. 10.5152/tjg.2019.19677
AMA	Bor S,KALKAN İ,ÇELEBİ A,Dincer D,Akyuz F,dettmar p,ÖZEN H Alginates: From the ocean to gastroesophageal reflux disease treatment. Turkish Journal of Gastroenterology. 2019; 30(2): 109 - 136. 10.5152/tjg.2019.19677
Vancouver	Bor S,KALKAN İ,ÇELEBİ A,Dincer D,Akyuz F,dettmar p,ÖZEN H Alginates: From the ocean to gastroesophageal reflux disease treatment. Turkish Journal of Gastroenterology. 2019; 30(2): 109 - 136. 10.5152/tjg.2019.19677
IEEE	Bor S,KALKAN İ,ÇELEBİ A,Dincer D,Akyuz F,dettmar p,ÖZEN H "Alginates: From the ocean to gastroesophageal reflux disease treatment." Turkish Journal of Gastroenterology, 30, ss.109 - 136, 2019. 10.5152/tjg.2019.19677
ISNAD	Bor, Serhat vd. "Alginates: From the ocean to gastroesophageal reflux disease treatment". Turkish Journal of Gastroenterology 30/2 (2019), 109-136. https://doi.org/10.5152/tjg.2019.19677